High prevalence of oral human papillomavirus infection in Fanconi's anemia patients

• Published in: Oral diseases Vol. 17; no. 6; pp. 572 - 576
• Main Authors: de Araujo, MR, Rubira-Bullen, IRF, Santos, CF, Dionísio, TJ, Bonfim, CMS, De Marco, L, Gillio-Tos, A, Merletti, F
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2011; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Alphapapillomavirus - classification; Anemia; Anemia, Aplastic - therapy; Bone marrow; Child; Child, Preschool; DNA, Viral - analysis; Fanconi anemia; Fanconi Anemia - complications; Fanconi Anemia - therapy; Female; Follow-Up Studies; Genotyping Techniques; Hematopoietic Stem Cell Transplantation; Human papillomavirus; Human papillomavirus 16; Human papillomavirus 16 - isolation & purification; Human papillomavirus 18 - isolation & purification; Human papillomavirus 6 - isolation & purification; Humans; Male; Middle Aged; mouth; Mouth Diseases - virology; oral; Papillomavirus Infections - complications; Polymerase Chain Reaction; Young Adult
• ISSN: 1354-523X; 1601-0825; 1601-0825
• DOI: 10.1111/j.1601-0825.2011.01803.x

Oral Diseases 17, 572–576 Background:  Fanconi’s anemia (FA) is a rare recessive genetic disorder characterized by bone marrow failure, developmental and congenital abnormalities, which frequently evolves to aplastic anemia and neoplasias, primarily acute leukemia and head‐neck carcinomas. Risk of malignancies increases after hematopoietic stem cell transplantation (HSCT), and the role of human papillomavirus (HPV) in FA carcinogenesis have been proposed. Objective:  To investigate prevalence of oral HPV in FA patients without oral malignant lesions. Materials and methods:  After oral examination, 76 subjects without detectable oral malignant lesions were included and classified in four groups: 20 FA submitted to HSCT (I), 22 FA not submitted to HSCT (II), 18 severe aplastic anemia (SAA) submitted to HSCT (III) and 16 healthy subjects (IV). Liquid‐based cytology sampling, HPV screening by polymerase chain reaction and genotyping by reverse hybridization were performed. Results:  The HPV detection rates were: group I 35%, group II 27.3%, group III 38% and group IV 6.25%. Prevalence of high risk HPV types, mainly HPV16, was detected. Compared with control group, suggestions for increased likelihood of being HPV infected in SAA (OR = 9.55, 95% CI: 1.01–125.41) and FA patients submitted to HSCT (OR = 8.08, 0.83–72.29) emerged. Conclusion:  Patients without oral malignant lesions submitted to HSCT, have high prevalence of oral HPV. HPV screening and close follow up should be considered in these patients.